Kidney and Blood Pressure Research

Original Paper

Increased Risk of Chronic Kidney Disease in Elderly with Metabolic Syndrome and High Levels of C-Reactive Protein: Kahrizak Elderly Study

Fakhrzadeh H.a · Ghaderpanahi M.a · Sharifi F.a, b · Badamchizade Z.a · Mirarefin M.a · Larijani B.a

Author affiliations

aEndocrinology and Metabolism Research Center, Tehran University of Medical Sciences, and bUniversity of Social Welfare and Rehabilitation Sciences, Tehran, Iran

Related Articles for ""

Kidney Blood Press Res 2009;32:457–463

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: January 08, 2010
Issue release date: January 2010

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 3

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR

Abstract

Background: To explore the interrelationship between metabolic syndrome (MS), chronic kidney disease (CKD) and C-reactive protein (CRP) in an elderly Iranian cohort. Methods: 122 residents of Kahrizak Charity Foundation aged ≧60 years were enrolled in this survey. MS was defined according to the NCEP-ATPIII criteria. CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m2. CRP levels ≧3 mg/dl were determined as a high CRP. Results: The multivariate-adjusted odds ratio (OR) for CKD in MS was 5.81 (95% confidence interval (CI) 1.72–19.58) compared to those without MS. High blood pressure and high triglyceride levels were significantly associated with an increased risk of CKD (OR 4.01, 95% CI 1.55–10.37 and OR 3.27, 95% CI 1.25–8.53, respectively). Subjects with MS and high CRP levels had a 1.71-fold greater risk of having CKD compared to those without MS and low CRP levels (95% CI 1.02–2.84). Conclusion: There was a strong and independent relation between MS and risk of CKD in these elderly people. High blood pressure and hypertriglyceridemia increased the risk of CKD. Combination of high CRP and MS was strongly associated with an increased risk of CKD.

© 2010 S. Karger AG, Basel




Related Articles:


References

  1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
  2. Scott CL: Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003;92:35i–42i.
  3. Fakhrzadeh H, Ebrahimpour P, Pourebrahim R, Heshmat R, Larijani B: Metabolic syndrome and its associated risk factors in healthy adults: a population-based study in Iran. Metab Syndr Relat Disord 2006;4:28–34.
  4. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140:167–174.
  5. Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al: Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 2007;22:1100–1106.
  6. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K: Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006;69:369–374.
  7. Lee JE, Choi SY, Huh W, Kim YG, Kim DJ, Oh HY: Metabolic syndrome, C-reactive protein, and chronic kidney disease in nondiabetic, nonhypertensive adults. Am J Hypertens 2007;20:1189–1194.
  8. Wang Q, Chen X, Zhao Y, Gao K, Sun YG, Yang M: Association between metabolic syndrome and chronic kidney disease. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:618–622.
    External Resources
  9. Zhang L, Zuo L, Wang F, Wang M, Wang S, Liu L, Wang H: Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 2007;82:822–827.
  10. Rashidi A, Ghanbarian A, Azizi F: Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol 2007;2:976–983.
  11. Kitiyakara C, Yamwong S, Cheepudomwit S, Domrongkitchaiporn S, Unkurapinun N, Pakpeankitvatana V, et al: The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 2007;71:693–700.
  12. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al: Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006;48:383–291.
  13. Kurella M, Lo JC, Chertow G: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134–2140.
  14. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al: Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res 2007;30:937–943.
  15. Kidney Disease Outcome Quality Initiative: Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1–S246.
  16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
  17. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745–753.
  18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
  19. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
  20. Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97:3A–11A.
  21. Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group: A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:155A.
  22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
  23. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
  24. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58:293–301.
  25. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260–269.
  26. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002;62:1743–1749.
  27. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, et al: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482–1488.
  28. Keane WF, O’Donnell MP, Kasiske BL, Kim Y: Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993;4:187–194.
  29. Nishida Y, Yorioka N, Oda H, Yamakido M: Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 1997;29:919–930.
  30. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391–397.
  31. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–419.
  32. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK: Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005;46:577–586.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: January 08, 2010
Issue release date: January 2010

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 3

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP